GREY:ALEAF - Post by User
Comment by
Toweringmarson Sep 23, 2019 12:11pm
131 Views
Post# 30155057
RE:RE:RE:RE:I have v.high hopes for this stock but i don't understand SP
RE:RE:RE:RE:I have v.high hopes for this stock but i don't understand SPI dont think the clinics are allowed to solicit a certain company. So essentially we're footing the doctors bill to gather all the metrics involved in patient data. This can be a good thing in what we aim to do with our medical side, but its also adding up alot of overhead costs. I like that they posted revenue recently, but if they cant find a way to monetize this data then we've spent a ton of time collecting useless information in regards to research. IF they can find a way to monetize it we'll be in a genius position come time for it to be covered under insurance plans, but again, I fail to see how they're going to monetize it. Perhaps it will come out on the product formulation side, but we're still under health canada rules/regulations no matter how we look at it... So possibly a few minor tweaks to dosage?? I dont see that as being a major game changer. But I could be wrong. It may provide more validation on our FoliEdge academy stuff. But even that, how much revenue could that generate?? Its a real head scratcher.